Organon & Stock Intrinsic Value – Organon Stock Drops 4% Pre-Market After Q4 Earnings Miss Estimates in 2023.
February 20, 2023
Trending News 🌧️
Organon ($NYSE:OGN) has been affected by the downturn in their stock prices after the release of their fourth-quarter earnings figures. This came as a surprise to analysts and investors who had expected better results from the company. The decrease in profits has resulted in a 4% drop in Organon’s stock prices before the market opened on Thursday. This followed a generally positive trend in the company’s previous quarters, where they had seen steady growth and profitability. Investors and analysts fear that this decline could be the start of a negative trend in the company’s performance, and are concerned about whether it can be reversed in the upcoming quarter.
Organon’s management team has not yet given a clear explanation for the unexpected decrease in profits. This has led to speculation as to what has caused such a dramatic drop in earnings. Investors are now hoping that the company can find ways to reduce costs and increase revenue, so as to restore investor confidence in Organon’s stock.
Price History
ORGANON has seen a dramatic fall in its stock ahead of the market open after the company’s fourth quarter earnings fell short of analyst estimates in 2023. On Thursday, the stock opened at $27.8 and closed at $24.9, a plunge of 15.0% from its last closing price of $29.3. This has been met with mostly negative news coverage, as the selloff wipes away all of ORGANON’s gains for the year.
The news comes as a surprise to many investors who had high expectations for the company and were banking on its strong performance to drive further gains. Unfortunately, this was not the case, as the failure to meet expectations has caused a sharp decline in its share price. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Organon &. More…
| Total Revenues | Net Income | Net Margin |
| 6.17k | 917 | 16.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Organon &. More…
| Operations | Investing | Financing |
| 638 | -481 | -1.33k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Organon &. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 10.44k | 11.5k | -4.19 |
Key Ratios Snapshot
Some of the financial key ratios for Organon & are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -7.4% | -23.7% | 25.0% |
| FCF Margin | ROE | ROA |
| 2.2% | -90.5% | 9.2% |
Analysis – Organon & Stock Intrinsic Value
We, at GoodWhale, have conducted a financial analysis of ORGANON &. Our proprietary Valuation Line has resulted in the determination of an intrinsic value of $39.9 for a ORGANON & share. This suggests that the stock is currently undervalued, trading at a price of $24.9; a 37.5% discount to its intrinsic value. Our findings present an attractive opportunity for any investor looking to add ORGANON & to their portfolio. More…
Peers
Its competitors include Creso Pharma Ltd, NGL Fine-Chem Ltd, Willow Biosciences Inc, and other similar companies.
– Creso Pharma Ltd ($ASX:CPH)
Creso Pharma Ltd is a clinical stage pharmaceutical and nutraceutical company. The company focuses on the development, registration and commercialization of cannabis and hemp derived products. Creso Pharma Ltd has a market cap of 41.48M as of 2022, a Return on Equity of -38.64%. The company has a portfolio of products in various stages of development, including a CBD-based nutraceutical, a CBD-based animal health product, and a CBD-based topical cream.
– NGL Fine-Chem Ltd ($BSE:524774)
NGL Fine-Chem Ltd is a publicly traded company with a market capitalization of 8.71 billion as of 2022. The company’s return on equity is 13.3%. NGL Fine-Chem Ltd is engaged in the business of manufacturing and marketing of specialty chemicals. The company’s products are used in a variety of industries, including the automotive, aerospace, and construction industries.
– Willow Biosciences Inc ($TSX:WLLW)
Willow Biosciences Inc is a biotechnology company that develops and manufactures pharmaceutical ingredients. The company has a market capitalization of $14.85 million and a return on equity of -12.05%. Willow Biosciences is focused on providing sustainable, plant-based alternatives to traditional chemical manufacturing processes. The company’s products are used in a variety of industries, including pharmaceuticals, cosmetics, and food and beverage.
Summary
Organon stock dropped by 4% pre-market following the release of their fourth quarter earnings report in 2023, which fell short of market expectations. At the time of writing, news coverage has been primarily negative and the stock price has already dropped on the same day. Investors need to be aware of any potential risks and carefully review their strategies for investing in Organon. Short-term investors should pay close attention to the current market sentiment and potential regulatory changes, while long-term investors should assess any potential opportunities for growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
